

Formulation & Evaluation of Fast Dissolving Oral Thin Film of Ropinirole HCl

Dipak P. Savant

Department of Pharmaceuticals Chemistry and Technology, University Institute of Chemical Technology,
North Maharashtra University, Jalgaon

Abstract: *The present work aimed at preparing fast dissolving oral thin films of Ropinirole Hydrochloride with the purpose of developing a dosage form for a very quick onset of action, which is very convenient for administration, without the problem of swallowing and using water. The film of Ropinirole Hydrochloride was prepared by using polymers such as polyethylene oxide and glycerine as plasticizer, by a solvent casting method. The formulated fast dissolving films were evaluated for physical characteristics such as uniformity of weight, thickness, folding endurance, drug content uniformity, surface pH and percentage elongation, tensile strength using texture analyser. The formulations were subjected to disintegration, In-vitro drug release tests. The FTIR and DSC studies revealed that no physicochemical interaction between excipients and drug. Fast dissolving film of Ropinirole Hydrochloride containing polyethylene oxide as polymer showed (99.18 ± 0.78%) drug release at 60 sec. Percentage content uniformity (99.90 ± 1.25%). Fast dissolving films of Ropinirole Hydrochloride can be considered suitable for clinical use in the treatment of parkinson's disease and rest leg syndrome, where a quicker onset of action for a dosage form is desirable along with the convenience of administration.*

Keyword: Fast dissolving film of Ropinirole Hydrochloride, Polyethylene oxide, Solvent Casting method, Parkinson disease, Texture analyser, Atomic force Microscopy, XRD, and SEM (scanning electron microscopy).

1. Introduction

Fast-dissolving oral delivery systems are solid dosage forms, which disintegrate or dissolve within 1 min when placed in the mouth without drinking or chewing. The first developed fast-dissolving dosage form consisted in tablet form, and the rapid disintegrating properties were obtained through a special process or formulation modifications. [1] More recently, fast-dissolving films are gaining interest as an alternative to fast-dissolving tablets to definitely eliminate patients' fear of choking and overcome patent impediments.

Fast-dissolving films are generally constituted of plasticized hydrocolloids or blends made of thereof that can be laminated by solvent casting or hot-melt extrusion. According to the film forming material characteristics, the manufacture of the dosage forms can present different critical issues. Common problems are caused by foaming during the film formation due to the heating of the material or solvent evaporation, the flaking during the slitting and the cracking in the cutting phase. Furthermore, the films should be stable to moisture over time. Finally, to facilitate the handling they have to be flexible and exhibit a suitable tensile stress and do not stick to the packaging materials and fingers. Fast dissolving films offers an attractive route for systemic drug delivery. The improved systemic bioavailability results from bypassing first pass effect and better permeability due to a well supplied vascular and lymphatic drainage. Also large surface area of absorption, easy ingestion & swallowing, pain avoidance make the oral mucosa a very attractive and feasible site for systemic drug delivery. [2,3]

The delivery system consist of a very thin oral strip, which is simply based on the patient's tongue or any oral mucosal tissue, instantly wet by saliva the film rapidly hydrates and adheres onto site of application. It then disintegrates and

dissolves to release the medication. Ropinirole Hydrochloride is an orally active, dopamine receptor agonist used in the treatment of Parkinson disease. Parkinson's disease is one of the most baffling and complex of neurological disorders. [4] The term parkinsonism is used for a motor syndrome whose main symptoms are tremor at rest, stiffness, slowing of movement and postural instability. [5] Ropinirole Hydrochloride is the drug of choice used in the treatment of Parkinson disease. [5,6] By definition, a solid dosage form that dissolves or disintegrates quickly in the oral cavity, resulting in solution or suspension without the need for the administration of water, is known as an oral fast-dissolving dosage form. Mouth Dissolving Film is also known as Fast dissolving film, Quick dissolving film, Rapid dissolving film, Oral thin film (OTF), Orally Dissolving Films (ODF). Bioavailability of drug in film dosage form is greater than the conventional dosage form. [7] Oral films are also used for local effects like local anaesthetics for oral ulcers, toothaches, cold sores and teething. Generally the shelf life of film is 2-3 years it depends on the API added to the film but films are very sensitive to environmental moisture. [8]

Advantages: [9, 10, 11]

- 1) Oral cavity has large surface area which leads to rapid dissolution and disintegration of the oral dosage form.
- 2) No risk of choking.
- 3) OFDF is solid unit dosage form so provide accurate dosing and great precision.
- 4) Due to pre-gastric absorption the bioavailability of drug is improved and fewer doses are required which improve the patient compliance.
- 5) OFDF's does not require water to swallow so it has better acceptability among the dysphagic patients.
- 6) Provide good mouth feel.
- 7) Oral films are flexible and less fragile as compared to OFDF's so it can easily be transported and stored.

- 8) It avoid first pass metabolism as it directly absorb from the buccal mucosa and enter into the systemic circulation, side effects and dose are reduced.
- 9) Fast dissolving films disintegrate immediately within seconds when placed on tongue without the need of water and release one or more API.
- 10) Stability of the dosage form is enhanced.

Special features of oral films: [11,16]

- Ultra thin films
- Available in various size and shape
- Unobstructive
- Rapid release and fast disintegration
- Excellent mucoadhesion

Constraints of oral film: [12-14]

- High dose cannot be incorporated.
- Drug should have low dose.
- Should have high oral bioavailability.
- Oral films have expensive packaging.

The ideal properties of drug for the development of oral strips formulation:

- a. The drug should have low dose.
- b. The drug have extensive high first pass metabolism.
- c. It should be non-bitter.
- d. It should have quick onset of action.
- e. The drug should have high solubility and high permeability (BCS class I).

Applications: [14-17]

- a. Oral films are preferred for local action and also to manage pain, allergies, sleeping difficulty and CNS disorders.
- b. Dissolvable films are feasible for topical application for wound care as analgesics or antimicrobial agents.
- c. Oral films are applicable to enhance the bioavailability of poorly bioavailable drugs.
- d. Taste masking of bitter drugs.
- e. Dissolvable films are loaded with sensitive reagents to allow controlled release when exposed to a biological fluids or to create isolation barriers for separating multiple reagents to enable a timed reaction with a diagnostic device.

Primary concerns when manufacture Fast dissolving films [18, 19]

Selection of the API: It is very important part of the process. The selection of API depends on the potency of API, dose, as well as therapeutic efficacy. Most suitable API for ODF includes anti-allergic, antihistaminic, anti-parkinson, sleeping aids and analgesic drugs are preferred selection.

Selection of the Film formers: The film should be tough enough to physically handle and the robustness of the film depends on type of polymer used. Also the film has to be easily disintegrated in saliva or water to get immediate action. At least 45% w/w polymers should be present in the formulation in order to get good formulation. Along with various polymers Pullulan, gelatin, HPMC and HPC are the most commonly used polymers in film formulation.

Plasticizer: Plasticizer provides the efficient plasticity to the ODF formulation. One has to be careful in determining the plasticizer concentration. Selection plasticizer depends on compatibility citrate, PEG 400, glycerine and triacetin.

Taste masking: The taste masking is a prerequisite in the case of oral formulation. Natural as well as artificial sweeteners are used to improve the taste as well as intended to be dissolve and disintegrate in the oral cavity. The classical source of sugar is sucrose, fructose, glucose and dextrose. Saccharine, Sucralose and aspartame are fall in to the artificial sweetener category.

2. Materials and Methods

Ropinirole were received as gift sample from **wockhardt pharma, Aurangabad, India**. Polyethylene oxide (Aldrich Chemicals, Mumbai, India), Glycerine (Loba chemie, Mumbai, India) were purchased for carrying out various experiments. All other chemical were commercially available and used as received.

Methods

Pre-formulation studies

FTIR Spectroscopy

The FTIR spectrum of Ropinirole was recorded using FTIR spectrophotometer. The drug: KBr in a ratio of 1: 99 was taken & pallet was prepared using KBr press. This pallet was analyzed under IR spectrophotometer.

Drug-Excipient Compatibility Studies by DSC

DSC thermograms of pure drug (Ropinirole Hydrochloride) and its physical mixture with polymers (Ropinirole, PEO) were carried out to investigate any possible interaction between the drug and polymer. The selected heating rate is from 50°C to 300°C at an increase of 20°C per minute using Differential Scanning Calorimeter (shimadzu corporation, Japan). Differential scanning calorimetric (DSC) measurements were performed using a DSC in a temperature range of 25–250°C at a heating rate of 10°C/min in nitrogen gas. The melting points were calculated using a Stare Software from Mettler Toledo.

Standard Calibration curve for Ropinirole in phosphate buffer of pH 6.8

100 mg Ropinirole was accurately weighted & transferred to 100ml volumetric flask. Add sufficient quantity of phosphate buffer (pH 6.8) to dissolve drug & diluted to volume with phosphate buffer to give stock solution containing 1000µg/ml. 10ml of above stock solution was taken in 100ml volumetric flask appropriately diluted with phosphate buffer to obtain a concentration of 100µg/ml, 2, 4, 6, 8, & 10µg/ml prepared using stock solution of 100µg/ml. The above solutions were analyzed by U. V. Spectrophotometer at 250 nm. Phosphate buffer was used as a blank during spectrometric analysis.

Preparation of fast dissolving film by solvent casting method

Fast dissolving films of Ropinirole HCl were prepared by solvent casting technique using film forming polymer. Required amount of Polyethylene oxide according to the

formulation table was weighed accurately and soaked aside for 1 hour for swelling of polymer. Simultaneously Ropinirole HCl was weighed accurately and dissolved in 5ml of distilled water in another beaker. Then drug solution was added to the polymer solution and Glycerin was added as plasticizer and Sorbitol as sweetener, Citric acid as saliva stimulating agent mixed thoroughly with the help of magnetic stirrer. The above solution was sonicated for 20 min for removal of air bubbles. The glass mould (petridish) having diameter 9.5cm was placed over a flat surface and the resulting 10 ml solution with the help of measuring cylinder was transferred into petridish slowly drop by drop and was spread uniformly. Funnel was inverted and placed over the petridish to have uniform evaporation. The petridish

containing polymeric solution of drug was kept for 24 hours at room temperature for drying. The area of each film is 1×2 means 2cm^2 , so here we use the petridish having a diameter 9.5cm, radius 4.5cm so area of petridish was found to be,

$$\begin{aligned} \text{Area of Petridish} &= \pi r^2 \\ &= 3.14 \times 22.56 \\ &= 70.84\text{cm}^2 \end{aligned}$$

From the above calculation it was concluded that the each petridish contain 35 films so formula was developed as per 35 films for one batch.

Formula was developed for 35 films and each film contains 2 mg of RopiniroleHCl.

Table 1: Formulation Batches of Fast Dissolving Oral Film of Ropinirole HCl

Sr.no	Ingredient	F1	F2	F3	F4	F5	F6	F7	F8	F9
1	Ropinirole (mg)	70	70	70	70	70	70	70	70	70
2	PEO(mg)	150	150	150	200	200	200	250	250	250
3	Glycerin(ml)	0.1	0.2	0.3	0.1	0.2	0.3	0.1	0.2	0.3
4	Citric acid(mg)	25	25	25	25	25	25	25	25	25
5	Sorbitol(mg)	20	20	20	20	20	20	20	20	20
6	Strawberry (ml)	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
7	D\W	10	10	10	10	10	10	10	10	10

3. Evaluation of Fast Dissolving Films of Ropinirole HCl

Mechanical properties

Mechanical properties of films were evaluated using a Brookfield, USA texture analyzer equipment equipped with a 5Kg load cell. Films are held between two clamps positioned between 3cm. During measurement the films were pulled at rate of 2mm/sec. The force and elongation were measured when film breaks. Three mechanical properties namely tensile strength, elastic modulus and % elongation were calculated.

Tensile strength

Tensile strength is calculated by formula,

$$\text{Tensile strength} = \frac{\text{Load at failure}}{\text{Film thickness} \times \text{film width}} \times 100$$

% Elongation

It is calculated as,

$$\% \text{Elongation} = \frac{\text{Increase in length}}{\text{Original length}} \times 100$$



Figure1: Image of CT3 texture analyser used for measurement of mechanical properties.

Folding Endurance

This test was performed by cutting the mouthdissolving film of size $1 \times 2 \text{ cm}^2$. The films were folded at same place until it breaks apart. [20]

In-vitro disintegration studies

Disintegration time study was slightly modified to mimic the in-vitro and in-vivo conditions. For the study, film as per the dimensions $1 \times 2 \text{ cm}^2$ required for dose delivery were placed on a stainless steel wire mesh containing 10 ml distilled water. Time required for the film to break and disintegrate was noted as in-vitro disintegration time. Since, the film is expected to disintegrate in the mouth in presence of saliva; only 10 ml of medium was used. [21]

Weight variation test

1×2 cm² film was cut at three different places in the cast film. The weight of each film strip was taken and then weight variation observed. [22]

Surface pH Measurement

The surface pH of Mouth dissolving film is determined in order to investigate the possibility of any side effects in vivo. As an acidic or alkaline pH may cause irritation to the oral mucosa, it is determined to keep the surface pH as close to neutral as possible. A combined pH electrode is used for this purpose. Film is slightly wet with the help of water. The pH is measured by bringing the electrode in contact with the surface of the oral film. This study is performed on three films of each formulation and mean ± S.D calculated. [23]

Thickness Test

The thickness of the film can be measured by micrometer screw gauge at different 5 strategic locations. This is helpful in determination of uniformity in the thickness of the film & this is directly related to the accuracy of dose in the film. [24]

Uniformity of drug content

A film of size 1×2 cm² is cut and put in 30 ml of volumetric flask containing solvent. This is then shaken in a mechanical shaker for 1 hr to get a homogeneous solution and filtered. The drug is determined spectroscopically after appropriate dilution. [25]

In-vitro dissolution studies

The in-vitro dissolution studies were conducted using simulated saliva (300 ml). The dissolution studies were carried out using USP dissolution apparatus XXIV (Electrolab, Mumbai, India) at 37± 0.5°C and at 50 rpm using specified dissolution media. Each film with dimension 1×2 cm² was placed on a stainless steel wire mesh with sieve opening 700µm. The film sample placed on this sieve was submerged into dissolution media. Samples were withdrawn at 0, 15, 30 and 60 sec. time intervals and filtered through 0.45µm Whatman filter paper and were analyzed

spectrophotometrically at 250 nm. To maintain the volume, an equal volume of fresh dissolution medium maintained at same temperature was added after withdrawing samples. The absorbance values were converted to concentration using standard calibration curve previously obtained by experiment. The dissolution testing studies were performed in triplicate for all the batches. [21]

Scanning Electron Microscopy (SEM) [26]

The surface morphology of the fast dissolving film was observed with scanning electron microscope, (JEOL 5400, Tokyo, Japan). The samples were attached to the slab surfaces with double-sided adhesive tapes and the scanning electron photomicrograph was taken at 1000x magnification.

X-ray Diffractograms of Films

Powder X-ray diffraction spectra of the drug-loaded Mouth Dissolving films were prepared using a Rigaku DMAX powder diffractometer (J) with Cu-Kα radiation and a monochromator on the diffracted beam.

Atomic force Microscopy (AFM)

AFM topographic images of film were taken on a multimode AFM attached to a Nanoscope III electronics. The AFM probes used for this study were rectangular silicon probes with a nominal spring constant of 40 nN/nm.

4. Results and Discussion

Drug-Excipient Compatibility Studies by FT-IR

Pure drug Ropinirole Hydrochloride spectra showed sharp characteristic peaks at 1350 cm⁻¹ (CH₃ bending), 1456 cm⁻¹ (C=C stretching), 1700 cm⁻¹ (C=O stretching) and 3150 cm⁻¹ (N-H stretching) in shown (fig.2, 4). All the above characteristic peaks of drug appear in the spectra of all other spectra of drug with polymer mixtures and formulations of mouth dissolving film at the same wave number, indicating no modification or no interaction between the drug and the excipients.




Figure 2: FTIR spectra of Ropinirole HCl




Figure 3: FTIR spectra of Polyethylene Oxide




Figure 4: FTIR spectra of Ropinirole HCL & Polyethylene Oxide

DSC studies of RopiniroleHCl:

Samples were analyzed by DSC using shimadzu corporation, Japan. The samples were placed into a pieced aluminium sample container. The studies were performed under static air atmosphere in the temperature range of 50⁰C-300⁰C at a heating rate of 10⁰C per min. The peak temperatures were

determined after calibration with a standard. The DSC thermograph of ropinirole hydrochloride exhibits endothermic peak at 244.41⁰C (figure 5, 6) corresponding to its melting point. All polymer and drug mixtures showed endothermic peak 240⁰C to 255⁰C range. So, results indicate that weak interaction occurs between drug and polymer.




Figure 5: DSC thermogram of RopiniroleHCl




Figure 6: DSC thermogram of Ropinirole HCL and Polyethylene Oxide

Calibration curve of Ropinirole Hydrochloride in Phosphate buffer pH 6.8

Graph of absorbance Vs concentration was plotted and found to be linear over the range of 2 to 10 µg/ml indicating it is compliance with Beer's and Lambert's law with r^2 value 0.995. Results are shown in (table no. 2 and fig. 7).

Table2: Standard Calibration Curve of RopiniroleHCl in Phosphate buffer pH 6.8

Sr.no	Concentration	Absorbance
1	0	0
2	2	0.071
3	4	0.127
4	6	0.179
5	8	0.238
6	10	0.285




Figure 7: Calibration Curve of RopiniroleHCl in phosphate buffer pH 6.8

Table 3: Evaluation of Fast Dissolving Film Formulation Batches F1 to F9

Batches	Tensile Strength (g/mm ²)	% Elongation	Weight (mg)	Folding Endurance	In-vitro Disintegration time (sec)	Thickness (mm)	% Drug Content
F1	9.25 ± 0.038	22.29± 0.61	10.22± 0.77	97.25± 2.05	9.0± 1.00	0.05± 0.00	99.21± 0.65
F2	9.36 ± 0.112	25.82± 0.71	14.04± 1.53	105.24± 1.64	8.75± 0.00	0.06± 0.01	98.57± 0.13
F3	9.50 ± 0.050	30.62± 0.50	17.17± 0.75	92.28± 1.05	8.75± 0.57	0.05± 0.01	98.99± 1.25
F4	9.63 ± 0.070	33.99± 0.88	12.13± 0.50	99.78± 1.00	9.05± 0.58	0.05± 0.02	98.58± 0.71
F5	11.08 ± 0.094	37.21± 0.90	14.92± 0.60	94.67± 2.67	9.08± 0.00	0.05± 0.00	98.68± 0.67
F6	12.10 ± 0.111	39.80± 0.78	18.12± 1.53	94.30± 3.25	9.25± 1.00	0.05± 0.01	99.90± 1.25
F7	13.25 ± 0.158	48.21± 0.20	13.06± 1.28	85.00± 1.67	8.75± 0.00	0.06± 0.01	98.87± 0.25
F8	14.63 ± 0.091	50.93± 1.00	15.79± 0.28	88.20± 1.64	8.50± 0.58	0.06± 0.02	99.15± 0.26
F9	16.39 ± 0.115	52.56± 0.55	18.45± 0.53	98.90± 2.30	9.25± 1.00	0.06± 0.01	99.25± 0.13

Note: All values are mean ± SD, (n = 3)

Evaluation parameter

In vitro disintegrating time for fast dissolving film of PEO was ranges from 8.75± 0.00 to 9.25± 1.00 sec. Drug content in the films was evaluated and the values were found to be between 98.00 to 99.91 % shown in (table 3). All the fast dissolving formulations of different polymers are show

thickness value in the range of 0.05 ± 0.00 to 0.06 ± 0.02 mm.

Weight variation measurement

A result showed that as the concentration of polymer increases weight of film also increases shown in (table 3).

Surface pH

Surface pH of all fast dissolving films prepared by using PEO was found to be in the range of 6.0 to 7 pH, which was close to the neutral pH, which indicated that films may have less potential to irritate the sublingual mucosa, and hence, more acceptable by the patients.

Folding endurance

The flexibility of film is an important physical character needed for easy application on the site of administration. The flexibility of films can be measured quantitatively in terms of folding endurance and is determined by repeatedly folding the film at 180° angle of the plane at the same plane until it breaks. The number of times the film is folded

without breaking is computed as the folding endurance value. A result shown in (table 3) that as the concentration of polymer and plasticizer increases, folding Endurance of fast dissolving film increases.

Dissolution Studies

The studies of the formulation Batches from F1-F9 were carried out to know the in-vitro drug release pattern and the procedure was carried out as the procedure discussed earlier. The drug release at different time intervals was determined and calculated to know the release at variable concentration of polymers used. The results obtained were converted in the form of % drug release. The result was shown in (Table No.4 and Fig.No.8) Complete drug release with in 1 min.




Figure 8: Dissolution profile of formulation batches F1 to F9

Table 4: Cumulative % Drug Release*(SD) of Oral Fast Dissolving Film of Ropinirole.

Batches	In-vitro percentage drug release at 60 sec.
F1	86.21± 0.31
F2	87.24± 0.18
F3	89.30± 0.36
F4	84.15± 0.71
F5	86.83± 0.36
F6	99.18± 0.78

F7	97.53± 0.55
F8	95.47± 0.57
F9	89.30± 0.92

Environment scanning electron microscopy (ESEM)

SEM of optimized the film at 1000X magnification showed smooth surface with some little pores and without any scratches or transverse striations as shown in (fig. 9).




Figure 9: ESEM of optimized batch film at 1000xmagnification

X-ray Diffractograms of Film, drug and polymer

XRD analysis was performed to study the crystal structure of drug in the film. (Fig. 10) shows the spectra for drug compared when these drugs are incorporated into PEO films. The spectra obtained demonstrate that the drug in film has

crystalline characteristics that are preserved during processing. PEO resulted in significant increase the ropinirole bioavailability as compared to plain drug.




Figure 10: X-ray diffractograms

Atomic Force Microscopy

Ropinirole fast dissolving film obtained for various concentration of plasticizer condition were subjected to topographic analysis by means of atomic force microscopy. Fast dissolving film indicates variations in experimental

condition were not sufficient to affect shape dramatically. (Fig.11) Also shows the height and amplitude of single fast dissolving film.




Figure 11: Detailed, rotated AFM topographic three-dimensional image of fast dissolving ropinirole film. Horizontal, vertical and surface distance is shown

5. Conclusion

In present work, a Ropinirole HCl was selected for this investigation as novel drug dosage form for paediatric, geriatrics, and also for general population to improve bioavailability by preventing first pass metabolism, rapid onset of action. The main objective of study was to formulate and evaluate fast dissolving oral film of Ropinirole HCl by using polymer polyethylene oxide and plasticiser glycerine by solvent casting method.

Polyethylene oxide was found to be compatible with Ropinirole HCl, which was confirmed by FTIR spectroscopy. All formulations (F1 to F9) were evaluated for weight variation, thickness, drug content, disintegration time. Results of folding endurance, % elongation and tensile strength proved by texture analyser that when concentration of plasticiser and polymer are increased the flexibility of film also increases. From all evaluation parameter it was found that batch F6 show good physical appearance, texture and flexibility. Hence F6 batch can be selected as best batch. Results of In vitro drug release study reveals that batch F6 shows maximum drug release ($99.18 \pm 0.78\%$) within 60 seconds.

References

- [1] G. Sandri, M.C. Bonferoni, F. Ferrari, S. Rossi, C. Caramella, Differentiating factors between oral fast-dissolving technologies, *Am. J. Drug Deliv.* (2006),4 (4), 249–262.
- [2] H. S. Amir, *J. Pharm. Pharmaceut. Sci.*, (1998),1(1), 15–30.
- [3] B. K. Satishbabu, B. P. Shrinivasan, *Ind. J. Pharmaceut. Sci.*, 175-179 (2008).A. Arya, A. Chandra, V. Sharma, Kamla. Pathak, *International Journal of ChemTech Research.*, (2010), 2(1), 576-583.
- [4] Chandak C. Master of Sci. Thesis, “Orallydissolving film of selegiline hydrochloride”London Island University, May 2009.
- [5] Tripathi KD., *Essential of medicalpharmacology*, 5th Edn, Jaypee Brothers medicalPublisher, New Delhi; 2003; 135-144.
- [6] Gohel, M.C., “Development of taste maskedfilm of valdecoxib for oral use.” *Ind. J. Pharma.Sci.* 2007, 69(2), 320-323.
- [7] Okabe, H., Suzuki. E., Sugiur. Y., Yanagimoto.K., Takanashi. Y., Nogami E. et al.“Development of easily Swallowed filmformulation.”*Int. J. pharma.* 2008, 355, 62-66.
- [8] Malke M, Shidhaye & V J Kadam. Formulation andevaluation of Oxacarbazine fast dissolving tablets.*Indian journal of pharmaceutical sciences.* 2007;69(2): 211-214.
- [9] Kulkarni A S, Deokule H A, Mane M S and GhadgeD M. Exploration of different polymers for use inthe formulation of oral fast dissolving strips.*Journal of current pharmaceutical research.* 2010;2(1): 33-35.
- [10] Swapnilpatil, Paresh R mahaparale, Madhavi Ashivnikar, Shradha S Stiwari, Ketan V Pawar, Prashant N Sane. Fast dissolving oral films: aninnovative drug delivery system. *Internationaljournal of drug discovery and medical research*;2010; 1(1); 39-43.
- [11] Bradoo R. Fast Dissolving Drug Delivery Systems.*JAMA India* 2001; 4 (10): 27-31.
- [12] BhupinderBhyan, saritaJangra, MandeepKaur,harmanpreetsingh. Orally fast dissolving films:Innovation in formulation and technology.*International journal of pharmaceutical sciencesreview and research.*2011; 9(2):50-57.
- [13] Dipikaparumar, Upendrapatel, BhavinBhimni,AditiTripathi, DhirenDaslaniya, Ghanshyampatel.Orally fast dissolving films as dominant dosageform for quick release. *International*

- journal of pharmaceutical research and bioscience. 2012;1(3):27-41.
- [14] SwetaKalyan, Mayankbansal. Recent trends in the development of oral dissolving films. International journal of pharm Tech research.2012; 4(2): 725-735.
- [15] Vishwkarma DK, Tripathi AK, Yogesh P and Maddheshiya B. Review article on mouth dissolving films. Journal of global pharma Technology.2011;3(1):1-8.
- [16] Rathi Varun, Senthil V, Kammili Lavanya, Hans Ritu. A brief review on oral film technology. International journal of research in ayurveda and pharmacy. 2011; 2(4): 1138-1147.
- [17] M.D. Nehal Siddiqui, Garima Garg and Pramod Kumar Sharma. A Short Review on a Novel Approach in Oral Fast Dissolving Drug Delivery System and Their Patents. Advances in Biological Research, 2011, 5 (6): 291-303,.
- [18] Gavaskar, B., Vijayakumar, S. and Sharan, G., "Overview on fast dissolving films." Int. J. pharm. Pharma. Sci. 2010, 2(3), 29-33.
- [19] Mashru, R.C., Sutariya, V.B., Sankalia, M.G. and Parikh, P., "Development and evaluation of fast dissolving film of salbutamol sulphate." Drug Development and Ind. Pharm. 2005, 31, 25-34.
- [20] Nishimura, M., Matur, K., Tsukioka, T. and Yamashita, H., "In-vitro and In-vivo characteristics of prochlorperazine oral disintegrating film." Int. J. Pharma. 2009, 368, 98-102.
- [21] Mishra, R. and Amin, A., "Formulation Development of Taste-Masked Rapidly Dissolving Films of Cetirizine Hydrochloride" Pharma. Techn. 2009, 48-56.
- [22] Cilurzo, F., Cupone, I., Minghetti, P., Selmin, F. and Montanari, L., "Fast dissolving films made of maltodextrins", Euro. J. Pharm. Biopharm. 2008, 70(3), 895-900.
- [23] Dinge, A. and Nagarsenke, M., "Formulation and evaluation of fast dissolving films for delivery of triclosan to the oral cavity", AAPS Pharm. Sci. Tech. 2008, 9(2), 349-356.
- [24] Chen, M., Tirol, G., Schmitt, R., Chien, C. and Dualeh, A., "Film forming polymers in fast dissolve oral films" AAPS Annual meetings posters and papers, T3200, 2006.
- [25] Honary, S. and Orafi, H., "The effect of different plasticizer molecular weights and concentrations on mechanical and thermomechanical properties of free films" Drug Dev. Ind. Pharm. 2002, 28(6), 711-715.
- [26] Mashru C, Sutariya V, Sankali M, Parikh P. Development and evaluation of fast dissolving film of salbutamol sulphate. Drug Dev Ind Pharm. (2005), 31: 25-34.